CAMBRIDGE, MA / ACCESS Newswire / November 3, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the first patient has been dosed in a Phase 1/2 study of mRNA-2808, the Company’s investigational ...

Hosts David and Gina explore the unexpected origins of blockbuster diabetes and weight-loss drugs like Ozempic and Wegovy ...

Cardiovascular disease continues to be the leading cause of death worldwide. But advances in heart-failure therapeutics have ...

Moderna (MRNA) is scheduled to announce Q3 earnings results on November 6, before market open, with analysts’ consensus pointing to another quarter of losses. Analysts have projected a loss of -$2.16 ...

The most widely used COVID-19 vaccines may offer a surprise benefit for some cancer patients by boosting their immune systems to help fight tumors. Research reported recently in the journal Nature ...

Ionis Pharmaceuticals, Inc. shows promise with new drug launches and a robust pipeline. Click here to read IONS stock ...

The decades-long quest to harness the power of messenger RNA to enhance cancer treatment has focused primarily on its value ...

The start of the trial marks an expansion of the firm's oncology pipeline, and the firm hopes mRNA-2808 will be the first of many T-cell engagers in its portfolio.

I know how destructive unchecked addiction can be. All the victims of the ongoing opioid crisis do, too. And this is about more than addiction — as when rare but real cases of myocarditis appeared in ...

Cancer patients who got an mRNA COVID vaccine within a few months of their immunotherapy lived longer than those who did not, health records show.

Moderna (MRNA) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

The observation that mRNA vaccines can sensitize tumors to immunotherapy has researchers eager to test how mRNA’s ability to activate the immune system could be harnessed in oncology.